ZoomRx vs Verilogue: How HCP-Patient Conversation Research Has Changed

For years, Verilogue defined the category. Physician-patient dialogue research. Audio recordings. Transcripts. A database pharma teams could query when they wanted to understand what was being said inside the exam room.

The category was real, and the use case was sound. Traditional market research — NRx data, message recall surveys, ATU studies — captures what physicians report. Conversation research captures what they say. Those two things are not the same.

But the market has evolved. Brand teams are asking harder questions. And the tools available to answer them have changed. Here is how the leading HCP-patient dialogue research vendors compare today.

The Comparison: Six Dimensions That Matter to Brand Teams

The table below reflects publicly observed differences in approach across six dimensions: partnership model, data collection, HCP recruitment, platform, deliverables, and follow-up qualitative research.

Where the Methodology Gap Shows Up in Practice

The sharpest difference between ZoomRx and Verilogue is not in what data is collected — it is in how it is collected and what can be done with it.

Two examples from ZoomRx's published research illustrate the stakes:

NSCLC Treatment Decisions

In ZoomRx's NSCLC conversation analysis, a consistent pattern emerged across biomarker-positive and biomarker-absent conversations. When an actionable biomarker was present, the test result organized the recommendation — the physician required little additional persuasion. When no actionable biomarker was found, the physician had to build confidence differently: through reassurance, practical clarity, and expectation-setting.

Approximately 4 in 5 patient questions across NSCLC conversations clustered around daily routine, side effects, and practical disruption — not efficacy or mechanism. And when conversations moved from first-line to progression planning, physician narrative fluency dropped markedly. Not a knowledge gap. A rehearsal gap.

That level of finding does not emerge from a historical database of non-specific conversations. It requires fielding designed around the clinical moment you are trying to understand.

Vaccine Decisions

In ZoomRx's vaccine conversation research, the most consistent finding was structural: physicians who achieved same-visit vaccine acceptance followed a recognizable three-act sequence — authority anchoring, hesitancy navigation, and lifestyle continuity reassurance.

That last element — proactively telling patients they can go to the gym and eat normally — is what moves the outcome most consistently in the 60 seconds after a patient voices hesitancy. It is almost never addressed in standard HCP training materials.

Deferral was not driven by negative vaccine sentiment. It was driven by the absence of a present-tense reason to act. The physician who ended with "call my nurse when you're ready" left the patient fully informed — and fully uncommitted.

What Has Changed in HCP-Patient Conversation Research

The Verilogue model — broad, open database access during a contract period — was the first generation of this methodology. It solved the access problem. Brand teams could hear exam room conversations for the first time.

The second generation solves a different problem: commercial relevance.

Brand teams do not need a database of conversations. They need conversations about the clinical moments, patient segments, and treatment decisions that matter to their brand — fielded prospectively, analyzed against their specific objectives, and accessible in real time as the study runs.

That is the methodological case for ZoomRx's HCP-patient conversation research. Tailored prospective fielding. Selective recruitment from the client's target list. An AI-powered portal that lets brand teams query the conversation database throughout fielding. And customized analysis centered on the questions the brand team is actually asking.

Who Should Be Considering Alternatives to Verilogue

This comparison is most relevant for pharma brand teams that are:

1. Evaluating alternatives to Verilogue for pharma research — particularly for indication-specific or launch-window studies
2. Experiencing a gap between what HCP research reports and what field teams observe in actual conversations
3. Designing HCP training programs or field messaging and needing language that reflects real exam room dynamics
4. Looking for a Verilogue competitor that offers prospective fielding, real-time access, and integrated follow-up qualitative research

ZoomRx has conducted 135+ physician-patient conversation studies across 20+ specialties. The methodology is used by teams at leading global biopharma companies across oncology, vaccines, immunology, and rare disease.

Frequently Asked Questions